Startups
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
Overview
Location
United States, California, Palo Alto
Employees
11-50
Total raised
$225M
Founded date
2018
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 4, 2025 | Американский производитель электросамолетов Beta Technologies привлек $1 млрд в ходе IPO | Согласно заявлению, опубликованному в понедельник (которое подтвердило более ранний отчет Bloomberg News), акции были размещены по $34 за штуку, что выше маркетингового диапазона. Объем размещения был увеличен до 29,9 млн акций по сравнению... |
| Sep 22, 2025 | Big Pharma-backed MapLight plots IPO to advance neuro pipeline | MapLight Therapeutics has illuminated a path toward an initial public offering, filing with the Securities and Exchange Commission (SEC) on Sept. 19 to be listed on the Nasdaq under the ticker symbol "MPLT." Should the IPO go thro... |
| Jul 31, 2025 | Top 10 Startup and Tech Funding News – July 31, 2025 | It’s Thursday, July 31, 2025, and the funding spree shows no signs of slowing down. Today’s lineup puts a spotlight on where capital is flowing: into AI-native infrastructure, next-gen fintech, biotech breakthroughs, and robotics startups r... |
| Jul 28, 2025 | MapLight Therapeutics Raises $372.5M in Series D Funding | MapLight Therapeutics, a Redwood City, CA-based clinical-stage biopharmaceutical company, raised $372.5M in Series D financing. The round was led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional... |
| Mar 28, 2024 | MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER'S DISEASE PSYCHOSIS | Study to evaluate safety and tolerability of extended-release fixed dose combination ML-007/PAC with precision-matched release kinetics in advance of planned Phase 2 clinical trials ML-007/PAC dosing regimens to be assessed in healthy non-e... |
| Oct 30, 2023 | MapLight Therapeutics Closes $225M Series C Funding | MapLight Therapeutics, a San Francisco, CA-based clinical-stage biopharmaceutical company, raised $225M in Series C funding. The round was led by Novo Holdings, 5AM Ventures, Cowen Healthcare Investments and other investors. In connection w... |
Reviews 0
FAQ about MapLight Therapeutics, Inc.
When was MapLight Therapeutics, Inc. founded?
MapLight Therapeutics, Inc. was founded in 2018.
How much funding has MapLight Therapeutics, Inc. raised?
MapLight Therapeutics, Inc. has raised $225M in total across 1 funding round.
What has the press written about MapLight Therapeutics, Inc.?
Parsers VC has collected 7 articles mentioning MapLight Therapeutics, Inc., among them “Американский производитель электросамолетов Beta Technologies привлек $1 млрд в ходе IPO” (Nov 4, 2025) and “Big Pharma-backed MapLight plots IPO to advance neuro pipeline” (Sep 22, 2025).
Is MapLight Therapeutics, Inc. still active?
Yes, MapLight Therapeutics, Inc. is active; its latest activity on Parsers VC dates from Nov 6, 2025.